anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain the titled glass having excellent strength and appropriate for the artificial root of a tooth, etc., by compression-molding fine glass powder of MgO-CaO-SiO2-P2O5, heating the molded body in the sintering temp. region and then heating in the crystallization temp. region. CONSTITUTION:Less than 200-mesh glass powder contg., by weight, 7-16% MgO, 20-45% CaO, 41-50% SiO2, 8-30% P2O5, 0-5% B2O3, 0-5% F2 and 0-10% Al2O3 is prepared. Then the glass powder is compression-molded and the molded body is heated in the sintering temp. region of the glass powder and then heated in the crystallization temp. region to obtain the desired alkaliless crystallized glass for organisms. Consequently, many crystals of apatite, wollastonite, diopside, etc., are grown on the inside of the glass powder particles and from the surface to the inside and the glass of complicatedly enmeshed structure is obtained.
<P>PROBLEM TO BE SOLVED: To provide a technology for improving skin adhesion maintenance in a skin external preparation containing a powder of oil-in-water type emulsion dosage form.  <P>SOLUTION: The skin external preparation comprises (1) 0.05-5 mass% of an acyl lactic acid and/or its salt, (2) 0.1-10 mass% of an acylated polyglycerin, (3) 0.01-1 mass% of a sulfate-based anionic surfactant and (4) a powder. The powder is a powder having a hydroxyapatite-containing coating layer on the surface. The acyl lactic acid is preferably stearoyl lactic acid. The powder has the surface preferably subjected to at least one kind of a surface treatment selected from an N-acylamino acid salt coating treatment, a methylhydrogenpolysiloxane baking treatment and a silane coupling treatment with an alkylalkoxysilane.  <P>COPYRIGHT: (C)2008,JPO&INPIT
INTRODUCTION: Ascites, a severe complication of cirrhosis, significantly impacts patient morbidity and mortality especially in Black patients. Access to disease optimizing care has been proposed as a potential driver of this disparity. In this study, we evaluate TIPS utilization across racial and ethnic groups.
METHODS: We examined data from a 20% random sample of US Medicare enrollees with continuous Part D coverage. We required 180 days of continuous outpatient enrollment prior to cirrhosis diagnosis and all patients had ≥1 paracentesis within 180 days of their cirrhosis diagnosis. Time zero was the date of the first paracentesis. We assessed the likelihood of TIPS placement. Analyses were conducted to determine the independent associations between each outcome and race/ethnicity.
RESULTS: 5915 patients (average age 68.2, 64.4% male) were included in the analysis. 439 (7.4%) patients were identified as Black, 223 (3.8%) as Hispanic, and 4942 (83.6%) as white. When compared to white patients in a multivariable analysis, Black patients were less likely to receive a TIPS procedure (hazard ratio 0.4; 95% confidence interval (CI) 0.2-0.8) and had less days alive outside of the hospital (-100.5; 95% CI -189.4 - -11.6). There were no significant differences in transplant-free survival or number of paracenteses per year between ethnic and racial groups.
CONCLUSION: Black patients are less likely to receive a TIPS procedure when controlling for common patient- and disease-specific variables. Access to optimal specialized services may be a significant driver for disparities in outcomes of patients with cirrhosis between racial and ethnic groups.
Following a 2 week run-in period, participants were randomized to matching placebo to sotagliflozin administered as 2 tablets, once daily, before the first meal of the day, for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 106 weeks.
The aggregation of α-Synuclein (α-Syn) into amyloid fibrils is the hallmark of Parkinson's disease. Under stress or other pathological conditions, the accumulation of α-Syn oligomers is the main contributor to the cytotoxicity. A potential approach for treating Parkinson's disease involves preventing the accumulation of these α-Syn oligomers. In this study, we present a novel mechanism involving a conserved group of disorderly proteins known as small EDRK-rich factor (SERF), which promotes the aggregation of α-Syn through a cophase separation process. Using diverse methods like confocal microscopy, fluorescence recovery after photobleaching assays, solution-state NMR spectroscopy, and Western blot, we determined that the N-terminal domain of SERF1a plays a role in the interactions that occur during cophase separation. Within these droplets, α-Syn undergoes a gradual transformation from solid condensates to amyloid fibrils, while SERF1a is excluded from the condensates and dissolves into the solution. Notably, in vivo experiments show that SERF1a cophase separation with α-Syn significantly reduces the deposition of α-Syn oligomers and decreases its cellular toxicity under stress. These findings suggest that SERF1a accelerates the conversion of α-Syn from highly toxic oligomers to less toxic fibrils through cophase separation, thereby mitigating the biological damage of α-Syn aggregation.
is obtd. by culturing Streptomyces hygroscopicus 9735-1 in a suitable nutrient medium under aerobic conditions. The pH at the beginning of cultivation is pref. 6.5-7.5. and the cultivation temp. is pref. 27-31 degrees C. The amt. of DE-3936 accumulated reaches the max. in 65-110 hrs. cultivation. Recovery of the DE-3936 can be effected conventionally. Since the DE-3936 (in the form of free acid or its salt) is soluble in various organic solvents, the culture is treated with a suitable solvent, and the extract is then subjected to chromatography or recystallisation. Since the DE-3936 is contained in both the cultivated cells and culture filtrate, the culture is first sepd. into the cells and the filtrate. The cells are treated with methanol or acetone, and the filtrate is treated with benzene, chloroform, dichloroethane or ethyl acetate. DE-3936 in the form of sodium salt is obtd. as colourless prisms, and the structure is represented by the following formula: DE-3936 is effective for malaria, toxoplasma or coccidium infection and partic. effective against protozoa which are resistant to the currently used sulfa type drugs, quinoline type drugs or antithiamine.
The incidence of breast cancer is increasing annually, making it a major health threat for women. Chemoprevention using natural, dietary, or synthetic products has emerged as a promising approach to address this growing burden. Atractylenolide-III (AT-III), a sesquiterpenoid present in various medicinal herbs, has demonstrated potential therapeutic effects against several diseases, including tumors, nonalcoholic fatty liver disease, and cerebral ischemic injury. However, its impact on breast cancer chemoprevention remains unexplored. In this study, we used an N-methyl-N-nitrosourea (NMU)-induced rat breast cancer model and 17β-estradiol (E2)-treated MCF-10A cells to evaluate the chemopreventive potential of AT-III on mammary tumorigenesis. AT-III inhibited mammary tumor progression, evidenced by reduced tumor volume and multiplicity, prolonged tumor latency, and the reversal of NMU-induced weight loss. Furthermore, AT-III suppressed NMU-induced inflammation and oxidative stress through the Nrf2/ARE pathway in breast cancer tissues. In vitro, AT-III effectively suppressed E2-induced anchorage-independent growth and cell migration in MCF-10A cells. Nrf2 knockdown attenuated the protective effects of AT-III, highlighting the pivotal role of Nrf2 in AT-III-mediated suppression of tumorigenesis. The mechanism involves the induction of Nrf2 expression by AT-III through the autophagic degradation of Kelch-like ECH-associated protein 1 (Keap1). Overall, the results of this study indicate that AT-III is a promising candidate for breast cancer chemoprevention and provide valuable insights into its molecular interactions and signaling pathways.
ETHNOPHARMACOLOGICAL RELEVANCE: Zanthoxylum armatum DC. (Z. armatum) is an herbal medicine with various active ingredients and pharmacological effects. However, modern studies found that Z. armatum is hepatotoxic. The liver is the target organ for toxic effects and an important site for lipid metabolism. The effects of Z. armatum on lipid level and metabolism in the liver are still unclear.
AIM OF THE STUDY: This study aimed to analyze hepatic lipid levels, lipid metabolites and metabolic pathways of action of Z. armatum based on lipidomics, to investigate the potential hepatotoxic mechanism of Z. armatum.
MATERIALS AND METHODS: Different doses (62, 96, and 150 mg/kg) of the methanolic extract of Z. armatum (MZADC) were administered to ICR mice by gavage. The hepatotoxicity of MZADC was assessed by the liver index, serum biochemical measurements, and histopathological examination. Lipid levels measured by the serum lipid index were evaluated in the mice. Lipidomics was used to screen for differential lipid metabolism markers and lipid metabolism pathways in the liver. Western blot analysis was performed to investigate the effects of MZADC on the liver.
RESULTS: Liver index values and serum alanine transaminase and aspartate transaminase levels were increased in the MZADC group. Histopathology examination revealed hepatocyte necrosis, watery degeneration of the hepatocytes, and hepatic cord rupture in the livers of mice. Serum levels of low-density lipoprotein cholesterol, cholesterol, and triglycerides were elevated, and high-density lipoprotein cholesterol levels were decreased. Lipidomics screening for markers of differential lipid metabolism in the liver, and altered profiles of differential metabolites indicated that glycerophospholipid metabolism, linoleic acid metabolism, alpha-linolenic acid metabolism, glycosylphosphatidylinositol-anchored biosynthesis, sphingolipid metabolism and arachidonic acid metabolic pathways were significantly associated with MZADC-induced liver injury. Western blots confirmed that the protein expression of LC3, Beclin-1, ATG5, ATG12 and ATG16L1 was decreased, and p62 was increased in the MZADC group. The proportion of p-PI3K/PI3K and p-AKT/AKT was increased.
CONCLUSIONS: The liver injury induced by MZADC involved many different lipid metabolites and lipid metabolic pathways, which may be related to autophagy. This study provides a new perspective on the hepatotoxicity study of Z. armatum and provides a reference for the safe application of Z. armatum in the medicine and food fields.
In this single-arm study, patients will receive 7.4 GBq of 177Lu-PSMA-617 on Day 1 of every 6 week Cycle. Cabazitaxel will be administered concurrently on Day 2 and Day 23 of each Cycle (every 3 weeks). The dose of cabazitaxel will vary in dose-escalation. Up to 6 Cycles will be given.
A composition comprising the extract of Camellia sinensis var. assamica is provided to inhibit activity of alpha-glucosidase, suppress rapid increase of blood glucose level by delaying digestion rate of carbohydrates after meal without side effects, so that the composition is useful for preventing and treating diabetes mellitus. A composition for preventing and treating diabetes mellitus comprises 0.1-50 wt.% of the extract of Camellia sinensis var. assamica which is prepared by extracting Camellia sinensis var. assamica with a solvent selected from water, C1-C4 lower alcohol such as methanol, ethanol and butanol, and a mixture thereof, wherein the daily dosage of the Camellia sinensis var. assamica extract is 0.0001-100 mg/kg, preferably 0.001-100 mg/kg. Further, the composition is used for health function food.
We will retrospectively collect data from adults (≥18 years) admitted to a participating ICU prior to the COVID-19 surge in the country, who are invasively mechanically ventilated for more than 12 hours. We will include medical, surgical, trauma and neurological/neurosurgical patients who are COVID-19 negative.
Tablets for the controlled release of an active ingredient in a zero-order or near zero-order fashion are provided. The tablet includes a core and a coating. The core includes at least one active pharmaceutical agent and a polyethylene oxide with a molecular weight of between about 1,000,000 and 10,000,000, preferably between about 4,000,000 and 8,000,000. The core material is optionally, but preferably, coated with a cellulosic material. The active pharmaceutical agent can be hydrophilic, hydrophobic, or amphiphilic. When the active pharmaceutical agent is a hydrophilic agent, it is preferred that the coating is a relatively hydrophobic cellulose, such as ethylcellulose or propylcellulose. However, if the tablet is uncoated, it can provide a near-zero-order release rate rather than a zero-order release rate. When the active pharmaceutical agent is a hydrophobic or amphiphilic agent, the hydrophilic polymeric carrier is the same as in the first embodiment, the coating is a relatively more hydrophilic cellulose. The release rate for the active pharmaceutical agent can be controlled by adjusting the thickness of the coating, and, optionally, by adjusting the concentration of the polymeric excipients, as well as certain non-polymeric excipients which may optionally be present. An advantage of using relatively high molecular weight polyethylene oxide is that the release is pH independent, unlike where ionic polymers such as polyacrylic acids are used. Further, active pharmaceutical agents including functional groups that might react with such polymers can be used without an adverse reaction between the active agent and the polymer.
This invention relates to an isolated and purified serine/threonine kinase which is an integrin-linked kinase, designated "ILK". ILK can be used to modulate cell growth, modulate cell adhesion, modulate cell migration and modulate cell invasion. Inhibitors of ILK activity include (1) screens aimed at DNA, RNA or structural components of ILK, (2) pseudo-substrate inhibitors, such as a peptide which mimics a substrate sequence for ILK, and (3) drugs which specifically inhibit ILK  activity. The diseases treated by these inhibitors include cancer, leukemia, solid tumors, chronic inflammatory disease, arthritis, osteoporosis and cardiovascular disease. Diagnostics of ILK activity include DNA-based reagents derived from the nucleotide sequence of ILK and antibodies against ILK screen biopsy-derived samples of amplified ILK DNA, or increased expression of ILK mRNA or protein. Assays which screen drugs which specifically inhibit ILK activity are included within this invention.
BACKGROUND AND OBJECTIVES: Despite recent advances in understanding the gastric cancer (GC) biology, the precise molecular mechanism of gastric carcinogenesis and role of deregulated immune responses in GC progression are still not well understood. In this study, mRNA levels of human leukocyte antigen (HLA)-DRA and -DQA1 were assessed in GC patients to find a potential association between expression of these HLA-II molecules and gastric carcinogenesis.
METHODS: Using quantitative real-time (qRT)-PCR, mRNA levels of HLA-DRA and -DQA1 were assessed in 20 pairs of matched GC and normal tissues.
RESULTS: Our results showed that overall mRNA level of HLA-DRA was decreased in the tumor samples relative to control tissues (median fold change [FC] = 0.693; P = 0.445). Overall HLA-DQA1 level was increased in the tumor samples relative to control tissues (median FC = 1.659; P = 0.5117). However, the mentioned data were not statistically significant. Meanwhile, using a ≥ 2.5 FC as the cutoff to determine upregulation or downregulation, 35% of patients showed a downregulated expression of HLA-DRA, while 10% of those showed upregulation in HLA-DRA expression. Upregulation and downregulation of HLA-DQA1 expression were detected, respectively, in 35% and 25% of samples. A strong positive correlation was determined between HLA-DRA and HLA-DQA1 levels in tumor tissues (r = 0.7298; P = 0.0003).
CONCLUSION: The results reported here along with future studies can be useful to understand the interplay between immune system and GC, therefore, may be helpful to design an effective immune-based therapy.
PURPOSE: A composition containing chlorate is provided to safely and effectively treat porcine proliferative enteropathy. CONSTITUTION: A composition for treating porcine proliferative enteropathy contains 5-75 mM of chlorate. The composition additionally contains Prunus mume var alba extract or sodium nitrate. The Prunus mume var alba extract is obtained by adding water to Prunus mume var alba, heating, separating supernatant, and filtering. The concentration of the Prunus mume var alba extracts is 0.05-1.0%. The sodium nitrate is contained in 1-5 mM. The composition is used in the form of oral administration. The composition is administered in the amount of 0.1-100mg/kg once or several times a day.
The present invention discloses a preparation for curing fish bacterial infectious disease. The raw materials include 100 to 300g of Chinese teasel root, 10 to 100g of Chinese arborvitae leafy twig, 2 to 20g of Chinese gall and 50 to 500g of garlic. The present invention also discloses a preparation method: 1. Chinese teasel root, Chinese arborvitae leafy twig, Chinese gall and garlic are taken; 2. garlic is mashed, squeezed to get the juice and filtered if necessary and the garlic juice is taken as the active component I; 3. Chinese gall is added with vitriol liquid for regurgitant hydrolyzation and filtration and the filtrate is neutralized to be the active component II; 4. Chinese teasel root and Chinese arborvitae leafy twig are added with ethanol for regurgitant hydrolyzation twice and the liquid after two regurgitant hydrolyzations is respectively filtered; the filtrate of two times is mixed and decompressed to recover ethanol and condensed to be the active component III; 5. the active component II is heated for crystal precipitation and the crystal is melted and poured into the active component III so as to get the component IV; after cooling, the active component I is gradually added into the active component IV and added with purified water so as to get the solution.
The various embodiments herein provide a new method of selecting novel anti-cancer herbs using cheminformatics tools. The method involves collecting the herbs having synergistic activity with anti-cancer compounds and categorizing the herbs as synergistic plants (SP). The bioactive compounds are selected from the SP and categorized into synergistic compounds collection (SCC). A similarity search is performed using the selected bioactive compounds through available databases to select similar compounds that are categorized as similar synergistic compounds (SSC). A herbal source for the SSC is searched and categorized as similar herbal synergistic compounds (SHSC). The novelty of the SHSC in cancer treatment is confirmed. The novel herbs are categorized as novel candidate herbs (NCH). The synergistic activity of the resulted herbs (NCH) is confirmed by performing in vitro bioassay.
Routine conventional physical therapy will be applied to patients in the vibration group in 4 weeks and 45 minutes sessions. In addition, right after the sessions, 3 days a week, 30 Hz. frequency vibration will be applied. A vibration session will be as follows; 6 sets of vibrations will be applied, including 1 set of 1 minute vibration and 2 minutes of rest.
It is well known that sedation is frequently required as a component of compassionate care in critically ill patients. Until now, there is no ideal sedation drug and every sedation drug has its advantage and disadvantage for long-term sedation in critically ill, mechanically ventilated patients. The sequential use of midazolam and propofol for long-term sedation was associated with a faster recovery, earlier extubation, shorter mechanical ventilation time and less cost of total ICU treatment compared with midazolam alone, The protocol was associated with less cost of pharmaceutical sedation compared with propofol alone. But, propofol and midazolam may cause respiratory depression and delirium. Both drugs should be stopped after the patient passed the screen of weaning from mechanical ventilation, then it would induce the stress response and agitation, it would cause prolonged sedation and delay extubation.

Dexmedetomidine is a centrally acting a2-receptor agonist, has less effect on arousability and respiratory depression. The purpose of this study was to evaluate effects, safety and cost of midazolam used alone or sequential use of midazolam and propofol/dexmedetomidine for long-term sedation in critically ill, mechanically ventilated patients.
The invention relates to novel aminocarboxylate ligands that are suitable for complexing with a radionuclide, and are useful as imaging agents for diagnostic purposes. In accordance with the present invention, a method of preparing a compound of formula (I): fac-[M(CO)3(OH2)3]+, wherein M is Mn, ?99mTc, 186Re or 188¿Re, involves reacting a metal in permetallate form with carbon monoxide and a reducing agent, wherein a mixture of a basic borate buffer and a reducing agent soluble in water but not substantially decomposed by water is solved in a water containing solvent system containing a solution of the metal in permanganate, pertechnetate or perrhenate form in the presence of carbon monoxide. The compound of formula (I) can be reacted with a ligand L¿x? to form a compound of formula (II): fac-[M(CO)3(X)2L1]?n¿, wherein M is as defined above, L¿x? is a multidentate ligand, and n is a charge of the ligand Lx increased with one + charge. The invention also is directed to novel compounds, and kits for carrying out the disclosed methods.
Urban sites will be eligible for the UAG model in which patients will be joined into a UAG group consisting of 30 people. Each UAG group will meet every two to three months at a designated site (either at the clinic facility or another site in the community). Patients will receive (a) group adherence counseling led by a lay HCW (b) two to three month supply of ART medications via a pharmacy tech (c) attendance record and symptom assessment. As in the CAG model, patients may be referred up-referred for care based on acute illness or patient preference. Patients will continue to visit the facility for a routine medical visit with a professional HCW every six months.
Ten patients admitted into the Acute Care of the Elderly (ACE) ward will be approached for inclusion in the study. Patients will be given written information about the trial. Nursing staff looking after these patients will be asked to utilise the device after vital sign measurements obtained from standard hospital equipment when conducting routine vital sign measurements. Nurses will do this for the duration of the admission of 7days, thus generating 28 paired data points for comparison.